Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Training Effects on Cardioplexol Administration in Cardiac Surgery
NCT03823521Phase 3Completed
- Sponsor
- Swiss Cardio Technologies
- Start
- Nov 2018
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of Cardioplexol in coronary artery disease (CAD) and heart valve disease, sponsored by Swiss Cardio Technologies. Primary endpoint: Major Deviation in Cardioplexol application. Started Nov 2018; status: completed.
02
Drugs
Cardioplexol
03
Conditions
coronary artery disease (CAD)heart valve disease
Beyond the preview
Go deeper on NCT03823521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03823521.